Intravitreal Sodium Iodate Injection for Primate AMD Model
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current animal models for age-related macular degeneration (AMD) in non-human primates do not accurately reflect human pathology, limiting the effectiveness of drug development and evaluation for AMD treatment.
Innovation Solution
Administering sodium iodate directly into the vitreous body of non-human primates to induce retinal degeneration similar to human AMD, specifically targeting the macula, while minimizing systemic effects, to create a more accurate animal model for AMD research.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sodium iodate is administered systemically or intravitreally to induce AMD-like retinopathy, then RPE degeneration can be achieved, but the model does not accurately reflect human AMD pathology and produces systemic effects
Solution Approach 1:
The patent applies local quality by administering sodium iodate specifically to the macular region of the retina through intravitreal injection, creating localized RPE degeneration that mimics the geographic atrophy pattern of human AMD. This localized administration ensures the toxic effect is confined to the target area (macula) while avoiding systemic distribution, thus achieving both high model accuracy and minimal systemic side effects
Solution Approach 2:
The patent segments the administration approach by dividing the dosing strategy into multiple small intravitreal injections rather than a single large systemic dose. This segmentation allows precise control over the distribution and concentration of sodium iodate in the vitreous body, ensuring that the toxin reaches the macular RPE cells in controlled amounts while minimizing systemic exposure through the blood-retina barrier
2Ease of manufacture
If rodent or rabbit models are used for AMD research, then experimental procedures are simpler and costs are lower, but the models do not reflect human AMD pathology since the macula is only present in primates
Solution Approach 1:
The patent creates an accurate copy of human AMD pathology by inducing geographic atrophy in the macula of non-human primates, which possess the same anatomical structure (macula with fovea) as humans. The resulting RPE degeneration pattern, characterized by well-defined areas of atrophy with hyperpigmented borders, replicates the hallmark features of human AMD, providing a faithful model despite the complexity of primate experimentation
3Productivity
If intense light is used to induce light-induced retinopathy, then retinal degeneration occurs, but the model does not accurately mimic the degenerative atrophy pattern of human AMD
Solution Approach 1:
The patent changes the key parameter from physical energy (light intensity) to chemical toxicity (sodium iodate concentration). Instead of using high-energy light exposure to induce retinal damage, the patent employs chemical toxicity of sodium iodate at specific concentrations (0.1-10 mg/μL) to selectively degenerate RPE cells. This parameter change produces a degenerative atrophy pattern that closely matches human AMD rather than the phototoxic damage pattern of light-induced retinopathy
Data Source
AI summary
An object of the present invention is to provide a method for producing a non-human primate model of AMD, a method for evaluating the efficacy of a test substance in the prevention or treatment of AMD using the AMD animal model produced according to this method, and a method for screening substances effective in the prevention or treatment of AMD using the aforementioned AMD animal model. The method for preparing the AMD animal model consists of administering sodium iodate into a vitreous body of a non-human primate, and the method for evaluating the efficacy of a test substance in the prevention or treatment of AMD consists of preparing a non-human primate model of AMD according to the aforementioned method for preparing an AMD animal model, and evaluating the efficacy of the test substance in the prevention or treatment of AMD using the resulting AMD animal model.